肌萎缩侧索硬化症治疗市场规模、份额和成长分析（按治疗方法、类型、分销管道和地区）- 产业预测 2025-2032

2023 年肌萎缩侧索硬化症治疗市场规模价值 7.1145 亿美元，预计将从 2024 年的 7.52 亿美元扩大到 2032 年的 11.7171 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.7%。

肌萎缩侧索硬化症 (ALS)，也称为卢格里格氏症，是一种进行性神经退化性疾病，由于中枢神经系统神经细胞受损而影响随意肌控制。症状包括肌肉痉挛、僵硬和无力，导致吞嚥、说话和运动等基本功能丧失。大约 90-95% 的 ALS 病例是散发性的，其余的是遗传性ALS (FALS)，具有很大的遗传成分，主要是由于 C9ORF72 基因突变造成的。目前，尚无可以治癒 ALS的治疗方法，但是，透过药物治疗和干细胞治疗等先进治疗方法进行症状管理非常重要，并有望推动全球 ALS 治疗市场的成长。持续的研究和创新对于应对这项挑战至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 技术进步
• 监管格局
• 专利分析

肌萎缩侧索硬化症治疗市场规模（依治疗方法）

• 市场概况
• 药品
• 干细胞治疗
• 物理治疗
• 语言治疗

肌萎缩侧索硬化症治疗市场规模（按类型）

• 市场概况
• 散发性 ALS
• 遗传性ALS

肌萎缩侧索硬化症治疗市场规模（依分销管道划分）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

肌萎缩侧索硬化症治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Mitsubishi Tanabe Pharma Corporation（Japan）
• Biogen Inc.（USA）
• BrainStorm Cell Therapeutics Inc.（USA）
• Amylyx Pharmaceuticals, Inc.（USA）
• Ionis Pharmaceuticals, Inc.（USA）
• Sanofi（France）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• F. Hoffmann-La Roche Ltd（Switzerland）
• AB Science（France）
• Sun Pharmaceutical Industries Ltd.（India）
• Orion Corporation（Finland）
• CORESTEMCHEMON Inc.（South Korea）
• Cytokinetics, Inc.（USA）
• MediciNova, Inc.（USA）
• Mitsubishi Chemical Group Corporation（Japan）
• Apellis Pharmaceuticals, Inc.（USA）
• Denali Therapeutics Inc.（USA）
• Genentech, Inc.（USA）
• Treeway BV（Netherlands）

结论和建议

Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 711.45 million in 2023 and is poised to grow from USD 752.0 million in 2024 to USD 1171.71 million by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder affecting voluntary muscle control due to nerve cell damage in the central nervous system. Symptoms include muscle twitching, stiffness, and weakness, leading to the loss of essential functions like swallowing, speaking, and mobility. Approximately 90-95% of ALS cases are sporadic, while familial ALS (FALS) accounts for the remainder, with significant genetic components, primarily the C9ORF72 gene mutation. While there is currently no cure for ALS, symptom management through medications and advanced therapies like stem cell treatments is critical and expected to fuel the growth of the global ALS treatment market. Continued research and innovation are essential in addressing this challenging condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Amyotrophic Lateral Sclerosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Amyotrophic Lateral Sclerosis Treatment Market Segments Analysis

Global Amyotrophic Lateral Sclerosis Treatment Market is segmented by Treatment, Type, Distribution Channel and region. Based on Treatment, the market is segmented into Medication, Stem Cell Therapy, Physical Therapy and Speech Therapy. Based on Type, the market is segmented into Sporadic ALS and Familial ALS. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Amyotrophic Lateral Sclerosis Treatment Market

The growth of the Amyotrophic Lateral Sclerosis (ALS) treatment market is anticipated to be significantly influenced by the increasing prevalence of the disease. Data from the Centers for Disease Control and Prevention (CDC) indicated that in 2016, approximately 14,500 to 15,000 individuals in the United States were living with ALS, with around 5,000 new diagnoses occurring each year. Furthermore, globally, ALS affects about 2 to 5 individuals per 100,000. The rise in sedentary lifestyles and a growing elderly population also contribute to the heightened demand for both targeted and symptomatic treatments, which will likely stimulate the ALS treatment market in the coming years.

Restraints in the Amyotrophic Lateral Sclerosis Treatment Market

The amyotrophic lateral sclerosis (ALS) treatment market faces several significant restraints that are likely to hinder its growth during the forecast period. The high cost of treatment is a primary concern, as ALS is a rare condition, leading to exorbitant expenses that can reach approximately $200,000 annually, including medication like Edaravone, which alone costs around $145,000. Additionally, there is a general lack of awareness regarding ALS, which further limits patient access to treatment options. Moreover, the uncertainty surrounding the effectiveness of these costly treatments, associated with low survival rates, presents a substantial challenge for market expansion and patient confidence.

Market Trends of the Amyotrophic Lateral Sclerosis Treatment Market

The amyotrophic lateral sclerosis (ALS) treatment market is witnessing significant growth driven by the increasing prevalence of neurodegenerative disorders amidst busy lifestyles and rising incidences of ALS. The expanding geriatric population, particularly vulnerable to such conditions, is further propelling market expansion. Additionally, various NGOs and private organizations are actively promoting awareness campaigns focused on ALS diagnosis and treatment, fostering a more informed patient base and enhancing market outlook. The emergence of targeted symptomatic treatments aimed at alleviating ALS symptoms is also contributing to market growth, reflecting a robust trend towards more personalized and effective therapeutic solutions in the ALS landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Advancement
• Regulatory Landscape
• Patent Analysis

Global Amyotrophic Lateral Sclerosis Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medication
• Stem Cell Therapy
• Physical Therapy
• Speech Therapy

Global Amyotrophic Lateral Sclerosis Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Sporadic ALS
• Familial ALS

Global Amyotrophic Lateral Sclerosis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Amyotrophic Lateral Sclerosis Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BrainStorm Cell Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amylyx Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CORESTEMCHEMON Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytokinetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediciNova, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Chemical Group Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Denali Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Treeway B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations